| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
The growth of several cancer cell lines can be inhibited by ganoderic acid D, which has an IC50 of 17.3 mM against the human cervical cancer cell HeLa[2]. Cell viability is lowered by ganoderic acid D (1–50 μM; 24-72 hours) in a dose- and time-dependent way [2]. G2/M phase arrest is induced by ganoderic acid D (10, 50 μM; 24, 48 hours) [2]. HeLa cell apoptosis can be induced with ganoderic acid D (10, 50 μM; 24, 48 hours) to produce the characteristic morphological alterations [2]. 10 μM; 48 hours) of ganoderic acid D upregulates PRDX3 and 14-3-3E[2].
|
|---|---|
| Cell Assay |
Cell viability assay [2]
Cell Types: HeLa human cervical cancer cell line (CCL-2) Tested Concentrations: 1, 5, 10, 20, 50 μM Incubation Duration: 24, 48, 72 hrs (hours) Experimental Results: diminished cell survival rate Dosage and Time-dependent, the IC50 value for 48 hrs (hours) treatment was 17.3 μM. Cell cycle analysis [2] Cell Types: HeLa human cervical cancer cell line (CCL-2) Tested Concentrations: 10, 50 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: Induced G2/M phase arrest. After 24 hrs (hours) of treatment with 10 μM, a cell cycle profile is shown with an increase in the G2/M cell population. Apoptosis analysis [2] Cell Types: HeLa human cervical cancer cell line (CCL-2) Tested Concentrations: 10, 50 μM Incubation Duration: 48 hrs (hours) Experimental Results: HeLa cells were induced to show typical apoptotic morphological changes. Western Blot Analysis[2] Cell Types: HeLa human cervical cancer cell line (CCL-2) Tested Concentrations: 10 μM Incubation Duration: 48 hrs (hours) Experimental Results: 14-3-3E and PRDX3 were upregulated. |
| References |
|
| Additional Infomation |
Ganodernic acid D is a triterpenoid.
GanodericacidD has been reported in Ganoderma applanatum with data available. |
| Molecular Formula |
C30H42O7
|
|---|---|
| Molecular Weight |
514.6503
|
| Exact Mass |
514.293
|
| CAS # |
108340-60-9
|
| PubChem CID |
14109406
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
688.3±55.0 °C at 760 mmHg
|
| Flash Point |
384.1±28.0 °C
|
| Vapour Pressure |
0.0±4.9 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
2.43
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CC(=O)CC(C)C(=O)O)[C@H]1CC(=O)[C@@]2([C@@]1(CC(=O)C3=C2[C@H](C[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)O)C)C
|
| InChi Key |
YTVGSCZIHGRVAV-IYAQLQCNSA-N
|
| InChi Code |
InChI=1S/C30H42O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21,32H,8-14H2,1-7H3,(H,36,37)/t15-,16?,18-,19+,21+,28+,29-,30+/m1/s1
|
| Chemical Name |
(6R)-6-[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~194.31 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9431 mL | 9.7153 mL | 19.4307 mL | |
| 5 mM | 0.3886 mL | 1.9431 mL | 3.8861 mL | |
| 10 mM | 0.1943 mL | 0.9715 mL | 1.9431 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
